Gate News message, April 15 — Amazon Web Services (AWS) has launched Amazon Bio Discovery, an AI application designed for early-stage drug discovery. The platform enables scientists to run computational workflows without coding and send shortlisted molecules to lab partners for synthesis and testing.
The product combines biological foundation models that generate and evaluate drug molecules with an AI agent that assists users in selecting models, setting parameters, and interpreting results. Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics. AWS Vice President for Healthcare AI and Life Sciences Rajiv Chopra stated that work previously requiring 18 months to produce 300 potential drug candidates can now be completed in a couple of weeks.
The service will begin with a free trial offering five experimental units before transitioning to subscription-based pricing tiers.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
Related Articles
Tesla China President Says Shanghai Plant Could Produce Humanoid Robots
Tesla's China President indicated that the Shanghai Gigafactory could manufacture humanoid robots in the future, aligning with CEO Musk's vision and China's national plan for robot production. Compliance with Chinese standards may lead to regional differences in robot development.
GateNews19m ago
Sam Altman-Backed Glydways Seeks $250M Funding at Over $1B Valuation
Glydways, an autonomous transit startup, seeks to raise $250 million after its $170 million Series C round. It develops self-driving vehicles for dedicated lanes and is expanding globally, including projects in Atlanta and Dubai.
GateNews47m ago
Indian AI Startup GobbleCube Raises $15M Series A Led by Susquehanna Venture Capital
GobbleCube, an AI startup from Gurugram, raised $15 million in Series A funding to enhance product development and AI research. Founded by ex-Blinkit executives, it has rapidly grown by partnering with over 400 brands and significantly increasing revenue since its launch.
GateNews1h ago
Boston Dynamics Integrates Google's Gemini AI into Spot Robot, Enhancing Autonomous Capabilities
Boston Dynamics unveiled demonstrations of its Spot robot enhanced with Google's Gemini AI, enabling greater autonomy in tasks like organizing and inspections. The integration of AI Vision Inspection and Learning improves Spot's environmental data analysis and operational efficiency.
GateNews1h ago
South Korean AI Startup Upstage Becomes Country's First AI Unicorn with $130M Series C
South Korean AI startup Upstage secured 180 billion won (around $130 million) in its Series C funding, achieving a valuation over 1 trillion won, becoming the country's first AI unicorn. The funds will expand infrastructure and support international growth.
GateNews2h ago
Google Chrome Adds Skills Feature to Save and Reuse Gemini Prompts
Google Chrome has introduced a feature called Skills, enabling users to save and reuse Gemini prompts across web pages. Initially available for English (US) users, it allows prompt edits and requires confirmation for certain actions. Competing browsers are entering the market, and Google is also offering preset Skills for various tasks.
GateNews2h ago
